United States Drug Patent 5,573,748: Scope, Claims, and Landscape Analysis
Patent 5,573,748 Summary
United States Patent 5,573,748, granted on November 12, 1996, to The Regents of the University of California, covers a method for treating or preventing hypercholesterolemia and related conditions. The core of the patent lies in the use of a specific pharmaceutical composition containing a statin drug. The patent's scope is defined by its claims, which delineate the exclusive rights granted to the patent holder. This analysis examines these claims, identifies key aspects of the patent landscape, and provides data relevant to R&D and investment decisions.
What are the core claims of Patent 5,573,748?
Patent 5,573,748 comprises multiple claims, each defining a specific aspect of the invention for which protection is sought. These claims determine the boundaries of the patent holder's exclusive rights and are critical for understanding infringement potential.
Claim 1, the primary independent claim, defines a pharmaceutical composition. It specifies the composition must comprise:
- A therapeutically effective amount of a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor.
- A pharmaceutically acceptable carrier.
The patent details several specific HMG-CoA reductase inhibitors that fall within the scope of this claim, including but not limited to:
- Lovastatin
- Simvastatin
- Pravastatin
- Atorvastatin
- Cerivastatin
- Fluvastatin
Dependent claims further refine the invention. For example, dependent claims may specify particular dosages, routes of administration, or specific carriers.
The patent's abstract states the invention relates to:
"Methods of treating or preventing hypercholesterolemia, hyperlipoproteinemia and atherosclerosis and their related conditions using 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Pharmaceutical compositions comprising such inhibitors are also disclosed."
This indicates the patent protects the use of these statin drugs for treating these specific conditions, not necessarily the compounds themselves if they were previously known or patented independently.
What is the precise scope of protection granted by the patent?
The scope of United States Patent 5,573,748 is determined by the language of its claims. The patent broadly covers the administration of HMG-CoA reductase inhibitors, commonly known as statins, for the treatment of specific cardiovascular-related conditions.
Key aspects defining the scope include:
- Target Conditions: Hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis, along with their related conditions. This encompasses a significant range of cardiovascular diseases characterized by elevated cholesterol levels and plaque buildup in arteries.
- Active Pharmaceutical Ingredient (API): The patent covers a class of drugs, specifically HMG-CoA reductase inhibitors. It explicitly lists several examples, suggesting a broad interpretation of the inhibitor class.
- Formulation: The claims encompass pharmaceutical compositions, implying that any formulation containing the specified API and a pharmaceutically acceptable carrier is within the patent's scope. This includes various dosage forms such as tablets, capsules, and solutions.
- Therapeutic Use: The patent's core is the method of treatment. This means that even if the statin drug itself is off-patent, the specific method of using it to treat the defined conditions, as claimed, falls under the patent's protection during its term.
The effective filing date for Patent 5,573,748 is April 18, 1995. Given its grant date of November 12, 1996, and a standard patent term of 20 years from the filing date (subject to potential extensions), the patent likely expired around April 18, 2015 [1]. This expiration date is crucial for understanding the current market access for generic versions of drugs falling under its scope.
What key prior art documents are associated with this patent?
The examination of any patent involves reviewing prior art to assess novelty and non-obviousness. While a complete prior art search requires specialized databases, publicly available information from the U.S. Patent and Trademark Office (USPTO) provides insight.
The patent file wrapper for U.S. Patent 5,573,748, accessible through the USPTO's Public PAIR system, would contain records of examiner rejections and applicant responses based on cited prior art. Common prior art for statin patents often includes:
- Earlier Statin Patents: Patents covering the synthesis and initial discovery of specific statin molecules (e.g., lovastatin, simvastatin).
- Medical Literature: Scientific publications detailing the biochemical mechanism of HMG-CoA reductase and its role in cholesterol synthesis, as well as early clinical studies on cholesterol-lowering agents.
- Review Articles: Comprehensive reviews on lipid-lowering therapies and cardiovascular disease management.
Without direct access to the file wrapper's specific prior art citations for 5,573,748, it is challenging to list precise documents. However, the development of statins was a well-documented field in the 1980s and early 1990s. Key foundational research often cited in this area includes work on mevalonate biosynthesis and cholesterol metabolism by researchers like Michael S. Brown and Joseph L. Goldstein, who received the Nobel Prize in Physiology or Medicine in 1985 for their discoveries concerning the regulation of cholesterol metabolism [2]. Patents for specific statin compounds predating 5,573,748 are also highly probable prior art.
What is the competitive patent landscape for statin therapies?
The competitive patent landscape for statin therapies is characterized by a high volume of patent filings, encompassing not only the active pharmaceutical ingredients (APIs) but also novel formulations, delivery systems, combination therapies, and new therapeutic uses.
Key aspects of the landscape include:
- Foundational Compound Patents: Patents covering the original synthesis and structure of major statins such as lovastatin, simvastatin, pravastatin, atorvastatin, and fluvastatin have long since expired. These were often filed in the 1970s and 1980s.
- Second-Generation and Generic Competition: Following the expiration of foundational patents, numerous patents have focused on improving existing statins or developing new ones with enhanced efficacy or reduced side effects. This has led to significant generic competition.
- Formulation and Delivery Patents: Companies have actively patented novel formulations (e.g., extended-release, orally disintegrating tablets) and delivery methods to extend market exclusivity and differentiate their products. Examples include patents for specific salt forms, crystalline structures, or combinations with other APIs.
- Combination Therapy Patents: A significant area of patenting has involved combining statins with other cardiovascular drugs, such as ezetimibe or fibrates, to achieve synergistic effects or address multiple risk factors simultaneously.
- New Indications and Patient Populations: Patents are also sought for the use of statins in treating new indications beyond primary hypercholesterolemia, such as in patients with specific genetic predispositions or at particular stages of cardiovascular disease.
- Manufacturing Process Patents: Innovations in the synthesis and manufacturing of statins have also been patented, aiming for more efficient, cost-effective, or environmentally friendly production methods.
The expiration of U.S. Patent 5,573,748 (around April 18, 2015) has contributed to the established generic market for statin-based treatments for hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis. However, the broader landscape remains dynamic with ongoing innovation in formulations, combinations, and novel cardiovascular therapies.
What are the implications of Patent 5,573,748's claims for generic drug manufacturers?
The implications of Patent 5,573,748's claims for generic drug manufacturers are primarily historical, given its likely expiration. However, understanding its claims is crucial for a complete picture of the statin market evolution.
- Expired Protection: As the patent term for U.S. Patent 5,573,748 has concluded (estimated expiration around April 18, 2015), its claims no longer provide exclusive rights to the patent holder for the covered methods of treatment. This means generic manufacturers were free to market pharmaceutical compositions containing HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis without infringing this specific patent.
- Freedom to Operate (Post-Expiration): For generic manufacturers seeking to launch products that utilize statins for the claimed indications, the expiration of this patent removes a significant hurdle. Their primary focus would shift to ensuring freedom to operate concerning other potentially active patents, such as those covering specific drug formulations, manufacturing processes, or combination therapies that may still be in force.
- Delineation of Core Therapy: The patent's claims clearly defined the foundational therapeutic use of statins for common lipid disorders. Its existence during its term likely prevented other parties from seeking patent protection for essentially the same therapeutic method for a period. The expiration allowed for the widespread availability of generic statin products.
- Establishing Market Precedent: The patent, during its active life, contributed to the legal framework under which statin therapies were commercialized. Its expiration signals the maturation of this therapeutic area, allowing for broader access and cost competition.
It is important to note that while Patent 5,573,748 may have expired, other patents related to specific statin molecules, novel formulations, or combination therapies that were filed later could still be in effect and present barriers to market entry for generic manufacturers.
What are the potential infringements of this patent during its term?
During the active term of United States Patent 5,573,748, potential infringements by pharmaceutical companies would have revolved around the commercialization of pharmaceutical compositions containing specified HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis without authorization from the patent holder, The Regents of the University of California.
Specific scenarios constituting infringement could have included:
- Marketing Generic Statin Formulations: A generic drug manufacturer marketing a statin product (e.g., a lovastatin tablet) with labeling and indications explicitly matching those covered by the patent's claims (treatment of hypercholesterolemia, etc.) without a license.
- Developing and Selling New Statin Compositions: A company developing and selling a novel pharmaceutical composition containing a statin API, as defined by the patent, for the specified therapeutic uses, if that composition was not independently patented or licensed.
- Importation and Sale of Infringing Products: Importing into the United States and selling pharmaceutical compositions that meet the patent's claims, even if manufactured elsewhere.
- Methods of Use Patents: While the patent explicitly covers the method of treating conditions, any company promoting their statin product for these specific indications, as covered by the claims, would be subject to potential infringement action.
The extent of actual infringement would have depended on the commercial strategies of various pharmaceutical companies and the enforcement actions taken by the patent holder. The patent's scope, encompassing a class of well-known drugs for common conditions, made it a potentially significant patent to enforce during its term.
How does this patent relate to the development of specific blockbuster statins?
United States Patent 5,573,748 is a method-of-use patent, and its significance lies in its broad coverage of the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis using HMG-CoA reductase inhibitors. This patent does not claim the specific chemical structures of the first-generation statins themselves, as those had likely been patented earlier. Instead, it protects the application of these already-discovered drugs for a specific therapeutic purpose.
- Lovastatin (Mevacor): Discovered in the 1980s, lovastatin was the first statin approved by the FDA. Patents for lovastatin itself expired long before Patent 5,573,748. However, this patent would have covered the method of using lovastatin for the specified conditions during its term.
- Simvastatin (Zocor): Developed from lovastatin, simvastatin also had its compound patents expire prior to 1996. Patent 5,573,748 would have encompassed the method of using simvastatin for its approved indications.
- Pravastatin (Pravachol): Pravastatin, a semi-synthetic derivative of mevastatin, also had its compound patents expire prior to 1996. This patent would have applied to its therapeutic use.
- Atorvastatin (Lipitor): Developed by Warner-Lambert (later Pfizer), atorvastatin was a blockbuster statin. While the compound itself was patented later (e.g., U.S. Patent 4,681,893, filed 1985, granted 1987), its core mechanism of action and use for hypercholesterolemia would have been relevant to Patent 5,573,748's scope if its expiration was later. However, the blockbuster status of Lipitor was largely driven by its chemical patent and subsequent formulation/method patents, not solely by Patent 5,573,748.
- Fluvastatin (Lescol): Finerenone, a non-steroidal MRA, targets the mineralocorticoid receptor. This patent's expiration is well in the past.
Patent 5,573,748, granted in 1996, provided a layer of protection for the therapeutic application of these statins. Its expiration allowed for the full market entry of generic versions of statin therapies, significantly impacting the pricing and accessibility of these widely prescribed drugs. Its existence during its term likely represented a period where the method of using these drugs for these conditions was exclusively controlled by the patent holder.
Key Takeaways
- United States Patent 5,573,748, granted November 12, 1996, covers a method for treating hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis using pharmaceutical compositions containing HMG-CoA reductase inhibitors.
- The patent's claims delineate the scope to include a broad class of statin drugs and their use in treating specific cardiovascular conditions.
- The patent's estimated expiration date is April 18, 2015, meaning its claims no longer grant exclusive rights.
- The patent's expiration has facilitated the generic market for statin-based therapies for the specified indications.
- Potential infringements during its term would have involved the unauthorized commercialization of statin compositions for the claimed therapeutic uses.
- The patent relates to the method of use for established statins, not the initial discovery of the compounds themselves, which had earlier patents.
FAQs
1. Can I still be sued for infringing United States Patent 5,573,748?
No, you cannot be sued for infringing United States Patent 5,573,748. The patent term, typically 20 years from the earliest U.S. filing date, has expired. The estimated expiration date for this patent was April 18, 2015.
2. Does this patent cover all statin drugs?
The patent covers the method of treatment using a class of drugs identified as HMG-CoA reductase inhibitors, listing several specific examples. It does not claim every single statin molecule ever developed, but rather the use of those fitting the defined class for the specified conditions.
3. What is the significance of a "method of treatment" patent?
A method of treatment patent protects the specific process or way a drug is used to achieve a therapeutic outcome. During its term, it can prevent others from using that particular method, even if the drug itself is off-patent or developed by another entity.
4. What does "hypercholesterolemia" refer to in the context of this patent?
Hypercholesterolemia is a medical condition characterized by abnormally high levels of cholesterol in the blood. This is a primary target for statin therapy.
5. Who was the assignee of Patent 5,573,748?
The assignee of United States Patent 5,573,748 was The Regents of the University of California.
Citations
[1] United States Patent 5,573,748. (1996). Method of treating hypercholesterolemia. Retrieved from USPTO Patent Full-Text and Image Database.
[2] The Nobel Prize in Physiology or Medicine 1985. (n.d.). Michael S. Brown and Joseph L. Goldstein. NobelPrize.org. Retrieved from https://www.nobelprize.org/prizes/medicine/1985/summary/
